| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PST.1753 |
| P698 | PubMed publication ID | 27264007 |
| P50 | author | Gaohong Dong | Q46433252 |
| P2093 | author name string | Marc Vandemeulebroecke | |
| P2860 | cites work | When is a seamless study desirable? Case studies from different pharmaceutical sponsors | Q50116411 |
| Evaluation of experiments with adaptive interim analyses. | Q52364596 | ||
| Multiplicity and flexibility in clinical trials. | Q53025596 | ||
| Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations. | Q54188469 | ||
| The Behavior of the P-Value When the Alternative Hypothesis is True | Q56337305 | ||
| A Multiple Comparison Procedure for Comparing Several Treatments with a Control | Q56838307 | ||
| Recursive Combination Tests | Q57305829 | ||
| On closed testing procedures with special reference to ordered analysis of variance | Q29041733 | ||
| Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). | Q30317994 | ||
| Optimizing the data combination rule for seamless phase II/III clinical trials | Q30860286 | ||
| Testing and estimation in flexible group sequential designs with adaptive treatment selection | Q36327917 | ||
| Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts | Q36593604 | ||
| Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer | Q36671812 | ||
| Group sequential and adaptive designs - a review of basic concepts and points of discussion | Q37229355 | ||
| Adaptive designs for confirmatory clinical trials | Q37389417 | ||
| Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. | Q38380750 | ||
| Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials | Q39961475 | ||
| Adaptive seamless designs with interim treatment selection: a case study in oncology | Q41498564 | ||
| Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility | Q42926272 | ||
| Comments on the draft guidance on "adaptive design clinical trials for drugs and biologics" of the U.S. Food and Drug Administration | Q43633505 | ||
| Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection | Q43920857 | ||
| An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints | Q44262116 | ||
| Unbiased estimation of selected treatment means in two-stage trials | Q44443386 | ||
| A varying-stage adaptive phase II/III clinical trial design | Q44494327 | ||
| A seamless phase II/III design with sample-size re-estimation. | Q45342085 | ||
| Dose selection in seamless phase II/III clinical trials based on efficacy and safety. | Q46029341 | ||
| Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment | Q46503414 | ||
| Adaptive sample size calculations in group sequential trials | Q47213254 | ||
| A comparison of two methods for adaptive interim analyses in clinical trials | Q48795595 | ||
| P433 | issue | 4 | |
| P921 | main subject | phase II clinical trial | Q42824440 |
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 368-378 | |
| P577 | publication date | 2016-06-05 | |
| P1433 | published in | Pharmaceutical Statistics | Q7180744 |
| P1476 | title | A modified varying-stage adaptive phase II/III clinical trial design | |
| P478 | volume | 15 |
Search more.